Mutations in FBN1 have been well identified in syndromic aortic dissection (AD) and familial thoracic aortic aneurysms and dissections. However, whether mutations of FBN1 contribute to sporadic non-syndromic AD and the characteristics of mutations remain unknown. Using next-generation-sequencing technology, FBN1 was sequenced in a total of 702 sporadic cases (including 687 of non-syndromic AD and 15 of sporadic Marfan syndrome with aortic event, and 527 normal controls). For the sporadic non-syndromic AD cohort, we found 26 variants in 27 patients (18 with missense, 2 frameshift, 1 initiation codon mutation, 3 nonsense and 3 splice site mutations). The prevalence of variants was significantly high in the sporadic nonsyndromic AD cohort (27/687, 3.9%). The patients with FBN1 mutations were younger, suffered from fewer risk factors such as hypertension and smoking, and were less gender partitioned than non-FBN1-mutation AD patients. The mutations were spread along the FBN1 gene in our sporadic non-syndromic AD cohort and mutation locations are not different between nonsyndromic and syndromic patients. These results demonstrate that the deleterious mutations in FBN1 largely contribute to pathogenesis of sporadic non-syndromic AD, which expands our knowledge of FBN1 variants and the genetic basis and pathology of AD.
Introduction
Aortic dissection (AD), which can be asymptomatic over time but can ultimately present as a medical and surgical emergency, is a life-threatening cardiovascular disease (1). The incidence suggested by population-based studies is approximately 3 cases per 100 000 people annually (2) . Previous studies have suggested that the common predisposing factors for AD are history of hypertension, old age, atherosclerosis and previous cardiovascular surgery (1, 3) . However, without large community-based disease and control groups, the precise relationship between AD and those predisposing factors remains unclear. The sum of risk factors most probably relates to a combination of inherited and acquired weakening of the aortic media and intimal disease (4) . Advances in genetic technology over the last two decades have revealed numerous genetic bases of AD. Inherited connective tissue disorders, such as Marfan syndrome (MFS) (FBN1), Loeys-Dietz syndrome (TGFBR1/2, SMAD2/3, TGFB2/3) and Ehlers-Danlos syndrome type IV (COL3A1), often predispose individuals to AD. Moreover, nearly 20% of AD patients who lack features of the genetic syndrome have affected first-degree relatives and several genes have been identified causing familial thoracic aortic aneurysms and dissection (5) . Of note, although sporadic cases of non-syndromic AD clearly exist, few studies have evaluated the genetic basis of those patients.
Fibrillin-1, known to be encoded by FBN1 gene, is a major structural component of extracellular matrix (ECM) microfibrils. FBN1 mutations are most commonly associated with MFS, as well as a proportion of patients with isolated ectopia lentis (6) and isolated skeletal features (7) . FBN1 mutations in isolated aortic aneurysm dissections have also been reported in a few cases (8, 9) . Very recently, genome-wide association studies have identified common genetic polymorphisms associated with sporadic thoracic aortic aneurysms and dissections at 15q21.1, a site that contains FBN1 (10) . Furthermore, as a biomarker, fibrillin-1 levels in circulation were significantly higher in those with acute or sub-acute dissection than those without dissection (11) . Taken together, these data suggest that FBN1 might contribute to sporadic AD without multi-system disorder.
There have been more than a thousand mutations identified in FBN1 (12) ; missense mutation is the most common type. However, obvious clustering has not been found and many of these mutations were unique to individual families. Meanwhile, the correlations of mutation types and locations with clinical characteristics have been investigated. Specifically, mutations cluster in exons 24-32 have been reported in neonatal MFS (13) . Although some other genotype-phenotype searches have been made in MFS, the full spectrum of FBN1 mutations and the exact correlations to phenotype are still subject to debate.
This raises important questions of interest: 1) What is the frequency of rare genetic variants of FBN1 in sporadic nonsyndromic AD patients? 2) Is there any distribution characteristic or genotype-phenotype association? In the present study, using a newly described, cost-effective targeted capture method, we sequenced FBN1 gene from a large case cohort that presented with sporadic non-syndromic AD and a control cohort to determine the contribution of variants in FBN1 gene to the pathogenesis of AD and their distribution in FBN1 gene. Additionally, we further assessed correlations between genotype and phenotype.
Results

Clinical characteristics
The group included 702 consecutive patients with sporadic AD. The study population of sporadic non-syndromic AD consisted of 687 probands. The mean age at diagnosis was 53.6 years (SD 611.9); 77.9% of the patients were male. 143 (20.8%) had dissection in both ascending and descending aorta (DeBakey I), 21 (3.1%) had dissection involving only the ascending aorta (DeBakey II), and 523 patients (76.1%) had dissection involving only the descending aorta (DeBakey III). In brief, 23.9% were Stanford type A and 76.1% were Stanford type B. For our 15 MFS patients, the mean age was 33.8 (SD 613.0) years old. Ten were ascending AD and five were descending dissection. The mean age of the control group was 54.1 (SD 611.3) years, and 77.2% were male (Table 1) .
Burden of mutations
We performed deep sequencing of the FBN1 gene on 687 individuals with non-familial non-syndromic AD and 15 MFS (sporadic syndromic AD), along with 527 healthy controls. A total of 26 FBN1 pathogenic/likely pathogenic mutations and 5 variants of uncertain significance (VUS) were identified. The mutations were identified in 27 sporadic non-syndromic AD patients, 26 of these were unique and two missense mutations were recurrent. The detection rate was 3.9%. The mutations comprised 18 (66.7%) missense, 1 (3.7%) initiation codon mutation, 3 (11.1%) nonsense, 2 (7.4%) frameshift and 3 (11.1%) splice site mutations. Of these 27 mutations, 8 were reported in the ClinVar database or HMGD or UMD (http://www.umd.be/FBN1/) (12, (14) (15) (16) (17) (18) . In the MFS cohort, 9 mutations were identified in 15 patients, 5 were missense, 3 were frameshift mutations and 1 was a splice site mutation. Four of nine were previously reported (18) (19) (20) (21) . None of large deletion/duplication was identified. In our control cohort, we identified one variant of uncertain significance. Neither truncating nor splicing variants were found in this group. All mutations were heterozygote (Table 2) . Compared with AD and control cohort, the cumulative odds ratio (OR) of the pathogenic/likely pathogenic mutations is 43.93 (95% CI 2.67-721.78); the burden P value is 6.16Â 10 À6 for sequence kernel association test (SKAT-O). The prevalence of mutations was lower in nonsyndromic AD than in MFS patients (27/687, 3.9% versus 9/15, 66.6%).
Pedigrees investigation
Since the patients were not young, most of the patients' parents were not alive and the DNA were not available. However, we still got two families (proband with c.3G>A or c.2557T>C, respectively) with their parents' DNA for further confirming the source of the mutations. Their parents were phenotype and genotype negative and the variants were de novo in those two families. At the same time, one big family (proband with c.7663G>A), in which the patient had five siblings, volunteered for segregation study. The relatives are all of wild-type. These pedigrees were showed in Supplementary Material, Figure S1 . Those family studies can partly imply the sporadic occurrence in de novo. Figure 1 . Detailed clinical and genetic information regarding the FBN1 mutation cohort is listed in Table 3 and Supplementary Material, Table S1 . VUS were listed in Supplementary Material, Table S2 .
Distribution of mutations
Clinical stratification
The clinical characteristics of the non-syndromic patients with versus without mutation were statistically different (Table 4) . 
Mutations types and phenotype
Previous studies have demonstrated that missense mutations substituting or creating a cysteine had significantly different phenotypes in MFS patients (18, 23, 24) . Some studies also explored the possibility of association with cardiovascular involvement but the results were negative (25) . Our results showed that 10 patients had 9 unique mutations that affected a cysteine, 2 of them sharing a novel missense mutation p.Cys853Arg in exon 21. Of these 10 patients, 60% (6/10) presented with a dissection of the ascending aorta, compared with 62.5% (5/8) of patients with non-cysteine missense mutations (P > 0.05). Likewise, the age in the Cys missense group was younger than that in the groups with non-Cys missense (43.89 versus 46.00 years). However, this difference did not reach statistical significance (Supplementary Material, Table S3 ). Protein-truncating mutations included both nonsense and frameshift, and were predicted to have a strong effect on protein structure and function. However, the protein-truncating mutations were only identified in five patients (18.5%) who were with Type B dissection. We also found an initiation codon mutation in FBN1, which was identified in a 27-year-old female proband with Type B dissection. When truncating/splicing/ initiation codon mutations were compared with missense mutations, there were no significant differences with respect to age or the location of aortic lesions, although the mean age tended to be younger (42.43 versus 44.88 years) (Supplementary Material, Table S3 ).
Location of mutations and phenotype
Being the central stretch of contiguous EGF-like domains, exons 24-32 were considered as a 'severe region' with complete phenotype (13) . However, there were only two patients (7.4%) with mutations in this region. None of our patients with mutations located in exons 24-32 presented with early onset of ascending-aortic lesion, which was the main characteristic of Table S3 ). In our study, 12 patients had a missense mutation in a cbEGF domain, with 66.7% patients having an ascending aorta involvement. We compared clinical characteristics between patients with a missense mutation in a cb-EGF domain and those with a missense mutation in a non-cb-EGF domain. No significant difference was observed. Similar negative results were found with analysis of all types of mutations (Supplementary Material, Table S3 ).
Discussion
In the current study, we sequenced the protein-coding regions of FBN1 gene and identified 26 variants in 27 of the 687 patients with non-familial non-syndromic AD. The burden of rare variants in this gene was high among patients (3.9%). We also identified differences in clinical variables of patients with mutations and those without mutations. Compared with the non-FBN1 mutation patients, carriers of any mutation were much younger and risk factors were less common. To the best of our knowledge, this study, with the largest cohort, accessed the frequency and distribution of pathogenic or likely pathogenic fibrillin 1 mutations in non-syndromic and non-familial AD patients in the Han Chinese population.
FBN1 mutations have been associated with a broad spectrum of clinical phenotypes. However, the majority of FBN1 sequencing studies have been limited to connective tissue syndrome cohorts. Our research, sequencing the largest group ever reported of patients with AD, for the first time indicated that the burden of FBN1 genetic variants with non-familial non-syndromic AD is high. In aggregate, approximately 1 in every 20 sporadic non-syndromic AD patients was a heterozygous carrier for 1 of the FBN1 variants. Consistently, having tested 102 AD patients by whole exome sequencing using a 21-gene panel for clinical purposes, Ziganshin et al. identified 6 FBN1 mutations (27) . Our results demonstrate that mutations in FBN1 predispose individuals to AD without systemic features. Namely, we highlight the significance of pathogenic or likely pathogenic mutations of FBN1 in non-syndromic AD and provide new evidence of the variable clinical presentations of FBN1 mutations.
In our study, there are obvious clinical distinctions between AD patients who have mutations in FBN1 versus no-FBN1 mutation patients. Firstly, the patients with FBN1 mutations were significantly younger than the non FBN1-mutation patients and had a higher trend toward type A of AD. This suggests that FBN1 mutation carriers suffered from earlier onset and severer disease. Secondly, although the male/female ratio was approximately 4:1 in all of our AD patients, which is consistent to previous report (1) , in FBN1 mutation group, the gender difference almost disappeared (the male/female ratio was 56/44). Furthermore, the usual risk factors, including hypertension and smoking status, were less common in the affected individuals. Hence, hypertension may not be the primary risk factor of AD with FBN1 mutations. In other words, treatment of risk factors such as hypertension in mutation carriers may not have the same effect on decreasing the risk of AD as in non-mutation patients. Overall, the phenotype with FBN1 variants is distinguishable from non-mutation AD. We speculated that the differences in clinical characteristics might reflect a different pathophysiologic process between mutation carriers and nonmutation. Genetic origin may partly explain why young patients, in the absence of common risk factors and syndrome/ family history, also suffered from AD, although further studies are needed to confirm this. It is well known that FBN1 mutations are common in patients with MFS. The detection rate for the FBN1 mutations in MFS ranges from 50 to 90%, depending on sample size, genetic background and sequencing methods (24, 28) . In our MFS patients, 9 out of the 15 (60%) have been detected with FBN1 mutations. Interestingly, the detection rate of FBN1 mutation (3.9%) is also considerable in the sporadic AD cohort. At the same time, the pedigree analysis for some of their parents and siblings also showed negative results. These results suggest that FBN1 mutations not only cause typical MFS but are also associated with the pathogenesis of sporadic AD. Given current Ghent nosology (29) , patients with the presence of both AD and a qualifying mutation in FBN1 can be diagnosed as MFS. Therefore, all of these 27 patients could be classified as MFS. With molecular diagnosis, the percentage of MFS increased from 2.1% (15/702) to 6.0% (42/702) in our cohort. Two Chinese studies, with 1003 and 2160 patients, respectively, reported 2.5% and 1.7% AD patients having MFS (30, 31) . For our consecutively recruited AD cohort, the frequency without molecular sequencing was 2.1%, which was in agreement with the previous studies. We have re-evaluated the history of the non-syndromic AD patients with FBN1 mutation status; only non-specific physical findings were observed. Without significant systemic features, FBN1 testing would not have been recommended based on physical evaluation alone (29) . Therefore, genetic predisposition of non-syndromic AD was greatly underestimated. The revised percentage in our study is higher than that of patients with MFS reported in other large clinical studies such as International Registry of Acute AD (IRAD) (1). Both ethnic differences and the complement of molecular diagnosis may explain the differences.
Non-syndromic AD caused by FBN1 mutation is distinct from AD with typical MFS. Firstly, patients with isolated ADs with FBN1 mutations were older than both our small cohort and the reported cohort of MFS (32), although disease developed at a significantly younger age than non-FBN1 mutations. Secondly, Individuals with FBN1 mutations in our cohort present with both type A and type B ADs. The aortic lesion in syndromic patients characterized by dilation of aortic root and ascending aortic, especially at the sinuses of Valsalva and the dilation may occurred throughout life (32) . Of note, the reason for clinical heterogeneity among individuals with mutations in FBN1 is unclear and requires further studies. There are likely additional environmental or genetic stimuli that explain the difference in clinical character.
Mutation types identified in our non-syndromic AD cohort were also found in typical MFS. As described previously in typical MFS, no specific type of mutation could be identified with a cardiovascular feature in European origin subjects (22) . In this study, all types of mutations were identified in sporadic AD cases. Previous study has demonstrated that most of the premature termination codon mutations and frameshift mutations lead to production of a reduced amount of normal functioning fibrillin-1 protein (haplo-insufficiency) (33), while most missense mutations lead to stable mutant fibrillin-1 protein [dominant negative (DN)] (34). Missense mutations affected a cysteine residue, and thus interfered with correct intra-domain disulfide bond formation, ultimately affecting the structural integrity of fibrillin-1 in the medial layer of the aorta. Recent evidences also indicated that fibrillins have multiple roles in the extracellular matrix, especially highlighted is the modulation of transforming growth factor b (TGFb) pathway in the aorta (35) . Thus, underlying pathophysiologic mechanisms, genetic and functional by which mutations in FBN1 result in syndromic disease, may be shared in non-syndromic AD.
Recent studies have showed the positive association between genotype and phenotype severity in patients with MFS. In a small cohort of MFS, Baudhuin and colleagues recently demonstrated that aortic event more frequently occurred with a nonsense or frameshift mutations (36) . Follow-up study showed that, MFS patients with haplo-insufficiency (HI) had a larger aortic root diameter at baseline and a faster aortic root dilation rate and are at increased risk for cardiovascular death and AD compared with patients with a DN mutation (37, 38) . However, age at any endpoint (cardiovascular death, AD, aortic surgery) did not significantly differ between groups (38). In our nonsyndromic AD cohort, both mutation types were identified and the age of AD showed insignificant difference. It indicated that all mutation types tend to have an increased risk for dissection. Considering the small cohort of mutation positive AD patients, HI mutation did not show a proportional advantage in our cohort and further studies are required to confirm.
The FBN1 mutations identified in our non-syndromic AD cohort were spread along the FBN1 gene without specific clustering. We analyzed the relation between clinical phenotype and the mutations in different regions and there was no significant difference. We also compared our findings with earlier reported mutations in MFS, and found that a decreased percentage of variants in exons 24-32 was observed in our sporadic AD cohort. We identified two mutations in this region and the percentage (2/27, 7.4%) was lower than that reported in a MFS cohort (20%), as 14.5% was expected based on the length of genomic sequence of the gene (22) . However, our study does not refute the importance of this region. Firstly, because most of the patients with neonatal MFS had mutations in exons 24-32 area (22) , those mutations in neonatal MFS have an increased percentage in the previous study. Secondly, while many aspects of a significant severe phenotype in MFS were identified, the probability of AD was not significantly different in regions from exons 24-32 when compared with the remaining regions (24) . In a word, exons 24-32 region of FBN1, as well as other regions, also is of great importance in sporadic AD.
It has been noted that the mutations within the 5' and 3' regions were mild due to low frequency and the low prevalence of aortic involvement in classic MFS (26) ; however, another study had different conclusions (28) . There were a total of 10 mutations occurring within the 5' and 3' regions in our study.
In patients with mutations located in these regions, no significant difference was found for any clinical parameter compared with mutations located elsewhere. Given that our patients all have AD, with life-threatening emergency, our results do not support the suggestion that this region is associated with a milder cardiac phenotype, although the numbers are small. Therefore, anyone presenting with an FBN1 mutation in those areas should also be considered at high risk of AD. A limitation to our study is that we only assessed mutations in FBN1 gene. Since our sequence panel includes but is not limited to FBN1, we found that 61.25% (430/702) patients have more than one pathogenic or likely pathogenic variant and these variants were distributed in 130 of the 152 resequencing genes, including known vascular disease genes, associated genes in TFG-b and NOTCH signaling pathway, cytoskeletal/smooth muscle contraction apparatus proteins and collagens-MMPs/ TIMP system (39) . Of all of them, FBN1 is ranked at the top, which explained 3.9% (27/687) sporadic non-syndromic AD patients. Further, the VUS need more familial segregation studies, and available structural or biochemical studies to evaluate the relevance. The mutation carrier also needs long-term follow-up to confirm the phenotype. Lastly, the mutation-affected cohort was not as large as other studies, although we sequenced the largest sporadic AD cohort so far. Further genotype/phenotype correlation validation is also needed in other populations.
In conclusion, our findings bridge the gap that existed in the literature for the relation between mutations in FBN1 and sporadic non-syndromic AD. We show an important clinical role for FBN1, which is significantly associated with sporadic nonsyndromic AD in younger patients. All types of mutation categories were identified, and these mutations were spread all along the gene in both sporadic non-syndromic AD and syndromic AD. For the genotype/phenotype correlations, considering that there are other modifiers to disease phenotype, this would require replication or confirmation in larger cohorts of patients with sporadic AD. We suggest that FBN1 is one of the most commonly indicated genes and should therefore definitely be included in genetic counseling for both syndromic and nonsyndromic AD.
Materials and Methods
Participants
This study, including protocol and methods, was approved by the ethics committees of the local hospitals and conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Guidelines for Good Clinical Practice. The 702 patients were recruited consecutively from Tongji Hospital, Wuhan, China, between 2008 and 2014. All patients were Han Chinese without consanguinity and had undergone MRI or CT examinations during diagnosis. Those patients included two cohorts: 1) 687 patients with nonsyndromic AD and 2) 15 cases of MFS with AD as comparison. Diagnosis of MFS was made according to Ghent criteria with clinical diagnosis (29) . All clinical data, including skeleton, skin, pulmonary and ophthalmic phenotypes, were collected by physician systematically, based on recent Ghent criteria. Mitral valve prolapse was screened by echocardiograph. We excluded patients with pseudo-aneurysm, lesions with aortitis, trauma, and infection. Patients with other syndromic AD were not included due to the small numbers available. All 702 patients reported the absence of a first-degree relative with aortic aneurysm or dissection. All patients provided written informed consent. Also, 527 unrelated Han Chinese healthy controls (control group) were enrolled randomly from individuals undergoing health examinations or individuals who were admitted to Tongji Hospital for reasons other than aortic diseases. All controls were without cardio-cerebrovascular disease history and had no family history of hereditary disease. Presence of aortic lesion was excluded by echocardiographic examination, echoaorta examination, or aortic computed tomography, MRI when deemed necessary by their physicians.
Next-generation sequencing
The FBN1 (NM_000138.4) exon sequence data were generated from next-generation sequencing. Genomic DNA was purified from peripheral blood lymphocytes (Qiagen, Germany). The primers were designed automatically by Ion AmpliSeq TM Readyto-Use custom designer platform. Library preparation and sequencing were performed as previously described (40 
Variant filter criteria
Non-synonymous variants with a rare allele frequency of <1% with absence of variant alleles either in the 1000-Genome project database, the NCBI dbSNP database, 5000 Exomes database or in our reference samples were taken for further analysis. All nonsense mutations, frameshift and splicing variants (intron þ1G orþ2T, À1G or À2A) were assessed to be pathogenic. Missenses were analyzed for pathogenicity according to the American College of Medical Genetics (ACMG) guideline (41) . We included the missense variants if the variant was located at a consensus cb-EGF or affected a cysteine amino acid as other studies have recognized (24) . We also took previous literature reported mutations and causal mutations in NCBI ClinVar database or HGMD database into consideration. The in silicobased computation analysis was carried out using PolyPhen-2 (and coded as possibly damaging or probably damaging) and SIFT (score of <0.05). Variants were classified as benign or likely benign if their frequency is greater than expected for disorder or the in silico protein predictions are neutral. Large deletion/duplication analysis was performed by data of amplicons coverage. All potential functional variants were confirmed by means of Sanger Sequencing using a BigDye Terminator Cycle Sequencing Kit and ABI 3130 capillary sequencer (Life Technologies).
Statistical analysis
We used either Fisher's exact test (for two-tailed analyses) or Pearson's chi-square test of association for categorical values.
Continuous variables were summarized as mean 6 SD and compared between groups by univariate analysis of variance. All statistical tests were two-sided, and a P value of 0.05 was considered statistically meaningful. OR and burden P value were performed with R(v.3.3.3) (42) and other statistical analyses were performed with SPSS 19.0 for Windows.
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